Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Lexeo Therapeutics (LXEO) Enterprise Value (2023 - 2026)

Lexeo Therapeutics' Enterprise Value history spans 2 years, with the latest figure at -$121.5 million for Q4 2023.

  • On a quarterly basis, Enterprise Value fell 57.06% to -$121.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$121.5 million, a 57.06% decrease, with the full-year FY2023 number at -$121.5 million, down 57.06% from a year prior.
  • Enterprise Value hit -$121.5 million in Q4 2023 for Lexeo Therapeutics, down from -$35.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for LXEO hit a ceiling of -$35.4 million in Q3 2023 and a floor of -$121.5 million in Q4 2023.